期刊文献+

血管紧张素转换酶抑制剂对血液透析患者贫血和促红细胞生成素用量的影响

Effect of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in hemodialysis patients
原文传递
导出
摘要 目的观察血管紧张素转换酶抑制剂(ACEI)对维持性血液透析患者贫血和促红细胞生成素(EPO)用量的影响。方法90例维持性血液透析合并高血压和贫血的患者,按随机数字表法分为观察组和对照组,每组45例,观察组使用ACEI降血压治疗,对照组使用钙离子拮抗剂(CCB)降血压治疗。比较两组患者在0、2、4、6、8、10、12个月时的血红蛋白、EPO用量、血清EPO。结果观察组的血红蛋白逐渐下降,6个月及之后与对照组比较差异有统计学意义[6个月:(94.21±9.20)g,L比(105.55±9.16)g/L;12个月:(95.90±6.75)g/L比(105.81±4.45)g/L;P〈0.05];观察组EPO用量逐渐上升,8个月及之后与对照组比较差异有统计学意义[8个月:(10090.75±1918.35)U,周比(7010.32±1600.15)U,周;12个月:(11586.39±2009.76)U/周比(7068.48±1615.35)U/周,P〈0.05]。在整个研究期间,两组患者的血清EPO水平均保持稳定不变。结论ACEI治疗会加重维持性血液透析患者的贫血和降低EPO的疗效。 Objective To observe the effect of angiotensin-converting enzyme inhibitors (ACEI) on anemia and erythropoietin (EPO) requirements in maintenance hemodialysis patients. Methods Ninety maintenance hemodialysis patients with hypertension and anemia were divided into 2 groups by random digits table, observation group (45 cases, using ACEI as antihypertensive treatment), control group [45 cases, using calcium channel blocker (CCB) as antihypertensive treatment]. The follow-up period after starting ACEI or CCB therapy was one year. The hemoglobin concentration, serum EPO, EPO requirements were compared after 0, 2, 4, 6, 8, 10, 12 months' treatment. Results In response to ACEI, the mean hemoglobin value in observation group decreased progressively, reaching statistical significance after 6 months, and it had significant difference compared with that in control group [6 months: (94.21 ± 9.20) g/L vs. (105.55 ±9.16) g/L,12 months: (95.90 ±6.75) g/L vs. (105.81 ±4.45) g/L,P〈0.05]. The EPO requirements experienced a progressive increase in observation group and reached statistical significance after 8 months, compared with those in control group [ 8 months: (10 090.75 ± 1918.35 ) U/week vs. (7010.32 ± 1600.15 ) U/week, 12 months : ( 11 586.39± 2009.76 ) U/week vs. ( 7068.48 ± 1615.35 ) U/week, P 〈 0.05 ]. Serum erythropoietin concentration remained stable during the study in two groups. Conclusion ACEI can worsen anemia and reduce the efficacy of EPO in maintenance hemodialysis patients.
出处 《中国医师进修杂志》 2011年第19期23-26,共4页 Chinese Journal of Postgraduates of Medicine
关键词 血管紧张素转换酶抑制药 红细胞生成素 贫血 肾透析 Angiotensin-converting enzyme inhibitors Erythropoietin Anemia Renal dialysis
  • 相关文献

参考文献12

  • 1孟建中,刘雷,李丹.从透析预后与实践研究(DOPPS)的结果看透析未来发展[J].中国血液净化,2006,5(3):125-127. 被引量:6
  • 2Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant, 2002,17 Suppl 11 :S39-43.
  • 3Cooper AC, Breen CP, Vyas B, et al. Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production. Nephrol Dial Transplant, 2003,18 ( 1 ) : 133-140.
  • 4彭隽,兰天飙,车华,余爱荣.ARB和ACEI维持性血液透析患者EPO疗效比较[J].药物流行病学杂志,2006,15(1):8-10. 被引量:4
  • 5Erturk S ,Nergizoglu G,Ates K, et al. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in hemodialysis patients. Nephrol Dial Transplant, 1999, 14(3) : 1912-1916.
  • 6Turkowski-Duhem A, Kamar N, Cointault O, et al. Predictive factors of anemia within the first year post renal transplant. Transplantation, 2005,80(7) :903-909.
  • 7Winkelmayer WC, Kewalramani R, Rutstein M, et al. Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol,2004,15(5 ) : 1347-1352.
  • 8Rossert J, Eckardt KU. Erythropoietin receptor: their role beyond erythropoiesis. Nephrol Dial Transplant, 2005,20(6) : 1025-1028.
  • 9Marusic VM, Dominis M,Jaksic B, et al. An giotensin-converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow. Br J Haematol, 2003,123 (3) : 539-541.
  • 10Naito M, Kawashima A, Akiba T, et al. Effects of an angiotensin Ⅱ receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol,2003,23(5 ) : 287-293.

二级参考文献25

  • 1钱家麒.关注血液透析中若干问题,进一步提高血液透析治疗水平[J].中华肾脏病杂志,2005,21(2):63-64. 被引量:30
  • 2Mrug M,Stropka T,Julian BA,et al.Angiotensin Ⅱ stimulates proliferation of normal early erythroid progenitors[J].J Clin Invest,1997,100(9):2310-2314.
  • 3Morrone LF,Dipallo S,Logoluso F,et al.Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients:role of growth factors and cytokines[J].Transplantation,1997,64(6):913-918.
  • 4Azizi M,Rousseau A,Ezan E,et al.Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline[J].J Clin Invest,1996,97:839-844.
  • 5Tsang WK,Tong KL,chan H W,et al.Blockde of angiotensin Ⅱ AT1 receptor reduces hematocrit in patients with posttransplant erythroeytosis[J].Transplantation Proc,1998,30(5):3072.
  • 6王海燕,王梅主编.慢性肾脏病及透析的临床实践指南[J].第1版.北京:人民卫生出版社,2003,22-51
  • 7S.Rao,W.B.Carter,D.L Mapes,et al.Development of Subscales from the Symptom/Problems and Effects of KidneyDisease Items in the Kidney Disease Quality of Life (K/DQOL) Instrument[J].Clinical Therapeutics,2004,22(9)1099-1111
  • 8Lopes AA,Bragg-Gresham JL,Satayathum S,et al.Health related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States:the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J].Am J Kidney,2003,41(3):605-15
  • 9Mapes DL,Bragg-Gresham JL,Bommer J,et al.Health related quality of life as a predictor of mortality and hospitalization:the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J].AmJ Kidney Dis,2004,44(3):54-60
  • 10D.L.Mapes,K.P.McCullough,D.Meredith,et al.Quality of life predicts mortality and hospitalization for hemodialysis (HD) patients in the US and Europe [J].American Society of Nephrology,1999,11(6):5-8

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部